Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. NLM AIDSLINE Important note: Information in this article was accurate in 1982. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis.

N Engl J Med. 1982 Sep 9;307(11):644-52. Unique Identifier : AIDSLINE MED/82272147
Mulley AG; Silverstein MD; Dienstag JL

Abstract: To formulate indications for the use of hepatitis B vaccine, we examined the cost effectiveness of three strategies: vaccinating everyone; screening everyone and vaccinating those without evidence of immunity; and neither vaccinating nor screening, but passively immunizing those with known exposure. Estimates of the hepatitis attack rate, prevalence of immunity, and frequency of known exposure were made for three representative populations: homosexual men, surgical residents, and the general population of the United States. Screening followed by vaccination of homosexual men and vaccination without prior screening of surgical residents would result in savings of medical costs. Neither screening nor vaccination is the lowest-cost strategy for the general population. Vaccination of susceptible persons will save medical costs for populations with annual attack rates above 5 per cent. Vaccination may be considered cost effective (or cost saving when indirect costs are included) for populations with attack rates as low as 1 to 2 per cent.
Keywords: Cost-Benefit Analysis Hepatitis B/ECONOMICS/IMMUNOLOGY/*PREVENTION & CONTROL Hepatitis B Virus/*IMMUNOLOGY Homosexuality Human Immunity, Natural Immunization, Passive Internship and Residency Male Models, Biological Risk Support, Non-U.S. Gov't Surgery United States Vaccination/*ECONOMICS Viral Vaccines/*ADMINISTRATION & DOSAGE JOURNAL ARTICLE

KWDcost-benefitanalysishepatitisb/economics/immunology/KWDprevention&controlhepatitisbvirus/KWDimmunologyhomosexualityhumanimmunity,naturalimmunization,passiveinternshipandresidencymalemodels,biologicalrisksupport,non-uKWDsKWDgov'tsurgeryunitedstatesvaccination/KWDeconomicsviralvaccines/KWDadministration&dosagejournalarticle
821230
M82C0010

Copyright © 1982 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1982. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1982. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .